FR-Pessac Cedex-CHUBORDEAUX
Welcome,         Profile    Billing    Logout  
 7 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pigneux, Arnaud
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
DEXAML-03, NCT03765541 / 2018-001467-23: Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

Terminated
3
73
Europe
Dexamethasone, Amsacrine, Cytarabine, Azacitidine
University Hospital, Toulouse
Relapsed or Refractory Acute Myeloid Leukemia
05/24
05/24
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
EPAG2015, NCT03603795: Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

Active, not recruiting
2
110
Europe
Eltrombopag, Arm Eltrombopag, Arm experimental A, Placebo, Arm placebo, Arm B
French Innovative Leukemia Organisation, Novartis Pharmaceuticals
Acute Myeloid Leukemia
06/22
07/26
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Terminated
2
66
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
08/24
08/24
CPX-351 TA-SMP, NCT04992949: Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Completed
2
42
Europe
CPX-351
French Innovative Leukemia Organisation, Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes
Acute Myeloid Leukemia, Myeloproliferative Syndrome
10/23
12/23
LAMSA2020, NCT04968015: Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission

Active, not recruiting
2
134
Europe
Cytarabine-Venetoclax Association, Cytarabine-Idarubicin Association
French Innovative Leukemia Organisation
Acute Myeloid Leukemia
08/25
01/29
KOMET-001, NCT04067336 / 2019-001545-41: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
199
Europe, Canada, US
Ziftomenib
Kura Oncology, Inc., Kura Oncology, Inc.
Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
10/28
10/28
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Dec 2022 - Dec 2023: Submission in US for relapsed/refractory acute leukemia
Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML
Checkmark Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/27
12/27
REM-422-102, NCT06297941: Study of REM-422 in Patients With AML or Higher Risk MDS

Recruiting
1
100
Europe, US
REM-422
Remix Therapeutics
Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
03/26
06/27
NCT06891144: Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy

Recruiting
N/A
1000
Europe
French Innovative Leukemia Organisation
AML, Adult
01/30
01/31
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pigneux, Arnaud
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
DEXAML-03, NCT03765541 / 2018-001467-23: Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

Terminated
3
73
Europe
Dexamethasone, Amsacrine, Cytarabine, Azacitidine
University Hospital, Toulouse
Relapsed or Refractory Acute Myeloid Leukemia
05/24
05/24
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
EPAG2015, NCT03603795: Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

Active, not recruiting
2
110
Europe
Eltrombopag, Arm Eltrombopag, Arm experimental A, Placebo, Arm placebo, Arm B
French Innovative Leukemia Organisation, Novartis Pharmaceuticals
Acute Myeloid Leukemia
06/22
07/26
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Terminated
2
66
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
08/24
08/24
CPX-351 TA-SMP, NCT04992949: Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Completed
2
42
Europe
CPX-351
French Innovative Leukemia Organisation, Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes
Acute Myeloid Leukemia, Myeloproliferative Syndrome
10/23
12/23
LAMSA2020, NCT04968015: Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission

Active, not recruiting
2
134
Europe
Cytarabine-Venetoclax Association, Cytarabine-Idarubicin Association
French Innovative Leukemia Organisation
Acute Myeloid Leukemia
08/25
01/29
KOMET-001, NCT04067336 / 2019-001545-41: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
199
Europe, Canada, US
Ziftomenib
Kura Oncology, Inc., Kura Oncology, Inc.
Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
10/28
10/28
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Dec 2022 - Dec 2023: Submission in US for relapsed/refractory acute leukemia
Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML
Checkmark Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/27
12/27
REM-422-102, NCT06297941: Study of REM-422 in Patients With AML or Higher Risk MDS

Recruiting
1
100
Europe, US
REM-422
Remix Therapeutics
Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
03/26
06/27
NCT06891144: Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy

Recruiting
N/A
1000
Europe
French Innovative Leukemia Organisation
AML, Adult
01/30
01/31

Download Options